跳转至内容
Merck
CN
  • Molecular evidence for OCT4-induced plasticity in adult human fibroblasts required for direct cell fate conversion to lineage specific progenitors.

Molecular evidence for OCT4-induced plasticity in adult human fibroblasts required for direct cell fate conversion to lineage specific progenitors.

Stem cells (Dayton, Ohio) (2014-04-18)
Ryan Mitchell, Eva Szabo, Zoya Shapovalova, Lili Aslostovar, Kennedy Makondo, Mickie Bhatia
摘要

Here we characterize the molecular and biological requirements for OCT4 plasticity induction in human skin derived fibroblasts (hFibs) that allows direct conversion of cell fate without iPSC formation. Our results indicate that adult hFibs not only require OCT4 but also short-term exposure to reprogramming media (RM) to successfully undergo direct conversion to early hematopoietic and neural progenitor fates. RM was found to be essential in this process and allowed for unique changes in global gene expression specific to the combined effects of OCT4 and treatment with reprogramming media to establish a plastic state. This molecular state of hFib plasticity was distinct from transient expression of a full complement of iPSC reprogramming factors consistent with a lack in molecular hallmarks of iPSC formation. Human Fib-derived OCT4 plastic cells display elevated levels of developmentally related genes associated with multiple lineages, but not those associated with pluripotency. In response to changes in the extracellular environment, plastic OCT4-expressing hFibs further activate genes involved in hematopoietic as well as tripotent neural progenitor biology that allow cell fate conversion. Our study provides a working definition of hFib-induced plasticity using OCT4 and a deconvoluted system to elucidate the process of direct cell fate reprogramming.

材料
货号
品牌
产品描述

Sigma-Aldrich
L-谷氨酰胺, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
L -抗坏血酸, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
毛喉素, from Coleus forskohlii, ≥98% (HPLC), powder
Sigma-Aldrich
L -抗坏血酸, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L -抗坏血酸, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
L -抗坏血酸, 99%
Sigma-Aldrich
毛喉素, For use in molecular biology applications
Sigma-Aldrich
L-谷氨酰胺, ReagentPlus®, ≥99% (HPLC)
Supelco
维生素C, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L -抗坏血酸, ACS reagent, ≥99%
Sigma-Aldrich
L -抗坏血酸, reagent grade, crystalline
SAFC
L-谷氨酰胺
Supelco
L -抗坏血酸, analytical standard
USP
抗坏血酸, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
L -抗坏血酸, reagent grade
Sigma-Aldrich
L -抗坏血酸, meets USP testing specifications
Sigma-Aldrich
L-谷氨酰胺, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
L -抗坏血酸, BioUltra, ≥99.5% (RT)
Sigma-Aldrich
L -抗坏血酸, FCC, FG
Sigma-Aldrich
L -抗坏血酸, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
维生素C, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L-谷氨酰胺, γ-irradiated, BioXtra, suitable for cell culture
Supelco
毛喉素, analytical standard
Sigma-Aldrich
L -抗坏血酸, puriss. p.a., ≥99.0% (RT)
Sigma-Aldrich
L-谷氨酰胺
Supelco
L-谷氨酰胺, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
2-苯基吲哚, technical grade, 95%
Supelco
L -抗坏血酸, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L -抗坏血酸, tested according to Ph. Eur.
Supelco
L-谷氨酰胺, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland